Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Dermatology,Oncology
Reference21 articles.
1. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor;Escandon;Int J Immunother Cancer Res,2017
2. Novel therapeutics for melanoma;Seetharamu;Expert Rev Anticancer Ther,2009
3. Mutations of the BRAF gene in human cancer;Davies;Nature,2002
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluating the Role of Neddylation Modifications in Kidney Renal Clear Cell Carcinoma: An Integrated Approach Using Bioinformatics, MLN4924 Dosing Experiments, and RNA Sequencing;Pharmaceuticals;2024-05-15
2. Cdk2 suppresses IL‐23 expression and the onset of severe acute pancreatitis;Immunity, Inflammation and Disease;2022-05-19
3. Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor;Frontiers in Oncology;2022-03-21
4. MLN4924 inhibits hedgehog signaling pathway and activates autophagy to alleviate mouse laser-induced choroidal neovascularization lesion;Biomedicine & Pharmacotherapy;2020-10
5. NEDD4 Negatively Regulates GITR via Ubiquitination in Immune Microenvironment of Melanoma;OncoTargets and Therapy;2019-12
NEDD4 Negatively Regulates GITR via Ubiquitination in Immune Microenvironment of Melanoma
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3